Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016

Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016
Published Jun 30, 2016
56 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016, provides in depth analysis on Leptin Receptor (OB Receptor or CD295 or LEPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Leptin Receptor (OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or pa

  
Source:
Document ID
GMDHC0242TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Leptin Receptor (OB Receptor or CD295 or LEPR) Overview71
Therapeutics Development83
  Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Stage of Development81
  Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Therapy Area91
  Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Indication101
Leptin Receptor (OB Receptor or CD295 or LEPR) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Companies132
Leptin Receptor (OB Receptor or CD295 or LEPR) Therapeutics Assessment157
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action162
  Assessment by Route of Administration182
  Assessment by Molecule Type202
Leptin Receptor (OB Receptor or CD295 or LEPR) Companies Involved in Therapeutics Development225
  Aegerion Pharmaceuticals, Inc.221
  Ambrx, Inc.231
  Jyant Technologies, Inc.241
  Neurotez, Inc.251
  XL-protein GmbH261
Leptin Receptor (OB Receptor or CD295 or LEPR) Drug Profiles2716
  ARX-328 Drug Profile271
  CV-0801 Drug Profile281
  CV-0802 Drug Profile291
  memtin Drug Profile302
  metreleptin Drug Profile325
  Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders Drug Profile371
  Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer Drug Profile381
  Recombinant Protein to Agonize Leptin Receptor for Alzheimer's Disease Drug Profile391
  Recombinant Protein to Agonize Leptin Receptor for Obesity Drug Profile401
  Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity Drug Profile411
  XL-100 Drug Profile421
Leptin Receptor (OB Receptor or CD295 or LEPR) Dormant Projects431
Leptin Receptor (OB Receptor or CD295 or LEPR) Discontinued Products441
Leptin Receptor (OB Receptor or CD295 or LEPR) Featured News &Press Releases4510
  Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease451
  Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin461
  Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin461
  May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy471
  Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy481
  Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer s Disease481
  Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy491
  Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy501
  Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy511
  Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy521
  Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy531
  Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes532
Appendix552
  Methodology551
  Coverage551
  Secondary Research551
  Primary Research551
  Expert Panel Validation551
  Contact Us551
  Disclaimer561

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Leptin-Receptor-OB-Receptor-or-CD295-or-LEPR-Pipeline-Review-H1-2016-2088-16119>
  
APA:
Global Markets Direct - Market Research. (2016). Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Leptin-Receptor-OB-Receptor-or-CD295-or-LEPR-Pipeline-Review-H1-2016-2088-16119>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.